Rilmazafone

This classification denotes a sedative and hypnotic with the molecular formula C21H20Cl2N6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CU3H37T766, chemically known as 5-((2-aminoacetamido)methyl)-1-(4-chloro-2-(o-chlorobenzoyl)phenyl)-n,n-dimethyl-1h-1,2,4-triazole-3-carboxamide but generally known as rilmazafone, which bears US NIH Compound Identifier 5069. European Medicines Agency schedules Rilmazafone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10315MIG. The term RILMAZAFONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). RILMAZAFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rilmazafone under HS 29339990 and SITC 51577. As of Q4 2014, RILMAZAFONE remains the US FDA Preferred Term for this commodity. Rilmazafone bears US NLM identifiers UMLS ID C0073378 and NCI Concept Code C76944. SMILES: CLC1CC(C(N2NC(NC2CNC(=O)CN)C(=O)N(C)C)CC1)C(=O)C1C(CL)CCCC1.